Guggulsterone and bexarotene induce secretion of exosome-associated breast cancer resistance protein and reduce doxorubicin resistance in MDA-MB-231 cells

International Journal of Cancer

Volumn 137, Issue 7, 2015, Pages 1610-1620

  Kong, Ji Na ^a   He, Qian ^a   Wang, Guanghu ^a   Dasgupta, Somsankar ^a,c   Dinkins, Michael B ^a   Zhu, Gu ^a   Kim, Austin ^a   Spassieva, Stefka ^b   Bieberich, Erhard ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c SAINT JAMES SCHOOL OF MEDICINE   (Anguilla)

Author keywords

bile acid; breast cancer resistance protein; cancer stem cells; doxorubicin; exosomes; multidrug resistance; nuclear receptors; sphingolipids

Indexed keywords

BEXAROTENE; BREAST CANCER RESISTANCE PROTEIN; CASPASE; CERAMIDE; DOXORUBICIN; GUGGULSTERONE; NEUTRAL SPHINGOMYELINASE 2; SPHINGOMYELIN PHOSPHODIESTERASE; UNCLASSIFIED DRUG; ABC TRANSPORTER; ABCG2 PROTEIN, HUMAN; PREGNA-4,17-DIENE-3,16-DIONE; PREGNANE DERIVATIVE; TETRALIN DERIVATIVE; TUMOR PROTEIN;

APOPTOSIS; ARTICLE; CANCER RESISTANCE; CHEMOSENSITIZATION; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; ENZYME ACTIVATION; EXOSOME; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN SECRETION; BIOSYNTHESIS; BREAST NEOPLASMS; CELL DEATH; DOWN REGULATION; DRUG EFFECTS; DRUG RESISTANCE; PATHOLOGY; SECRETION (PROCESS); TUMOR CELL LINE;

ATP-BINDING CASSETTE TRANSPORTERS; BREAST NEOPLASMS; CELL DEATH; CELL LINE, TUMOR; CERAMIDES; DOWN-REGULATION; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; EXOSOMES; HUMANS; NEOPLASM PROTEINS; PREGNENEDIONES; TETRAHYDRONAPHTHALENES;

EID: 84964698520     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29542     Document Type: Article

References (54)

1. Klaassen CD, Aleksunes LM,. Xenobiotic, bile acid, and cholesterol transporters: function and regulation. Pharmacol Rev 2010; 62: 1-96.
2. Choi YH, Yu AM,. ABC transporters in multidrug resistance and pharmacokinetics, and strategies for drug development. Curr Pharm Des 2014; 20: 793-807.
3. Lopes-Rodrigues V, Seca H, Sousa D, et al., The network of P-glycoprotein and microRNAs interactions. Int J Cancer 2014; 135: 253-63.
4. Bebawy M, Combes V, Lee E, et al., Membrane microparticles mediate transfer of P-glycoprotein to drug sensitive cancer cells. Leukemia 2009; 23: 1643-9.
5. Gong J, Jaiswal R, Mathys JM, et al., Microparticles and their emerging role in cancer multidrug resistance. Cancer Treat Rev 2012; 38: 226-34.
6. Jaiswal R, Luk F, Dalla PV, et al., Breast cancer-derived microparticles display tissue selectivity in the transfer of resistance proteins to cells. PLoS One 2013; 8: e61515.
7. Wright PK,. Targeting vesicle trafficking: an important approach to cancer chemotherapy. Recent Pat Anticancer Drug Discov 2008; 3: 137-47.
8. Stahl PD, Barbieri MA., Multivesicular bodies and multivesicular endosomes: the «ins and outs» of endosomal traffic. Sci STKE 2002; 2002: pe32.
9. Trajkovic K, Hsu C, Chiantia S, et al., Ceramide triggers budding of exosome vesicles into multivesicular endosomes. Science 2008; 319: 1244-7.
10. Wang G, Dinkins M, He Q, et al., Astrocytes secrete exosomes enriched with proapoptotic ceramide and prostate apoptosis response 4 (PAR-4): potential mechanism of apoptosis induction in alzheimer disease (AD). J Biol Chem 2012; 287: 21384-95.
11. Mager SELA, Breakefield I, Wood XO, et al., Extracellular vesicles: biology and emerging therapeutic opportunities. Nat Rev Drug Discov 2013; 12: 347-57.
12. Zhang HG, Grizzle WE,. Exosomes: a novel pathway of local and distant intercellular communication that facilitates the growth and metastasis of neoplastic lesions. Am J Pathol 2014; 184: 28-41.
13. Iqbal J, Chong PY, Tan PH,. Breast cancer stem cells: an update. J Clin Pathol 2013; 66: 485-90.
14. Morrison BJ, Schmidt CW, Lakhani SR, et al., Breast cancer stem cells: implications for therapy of breast cancer. Breast Cancer Res 2008; 10: 210.
15. Ischenko I, Seeliger H, Schaffer M, et al., Cancer stem cells: how can we target them? Curr Med Chem 2008; 15: 3171-84.
16. Gangopadhyay S, Nandy A, Hor P, et al., Breast cancer stem cells: a novel therapeutic target. Clin Breast Cancer 2013; 13: 7-15.
17. Spassieva S, Bieberich E,. The gut-to-breast connection-interdependence of sterols and sphingolipids in multidrug resistance and breast cancer therapy. Anticancer Agents Med Chem 2011; 11: 882-90.
18. Truman JP, Al Gadban MM, Smith KJ, et al., Differential regulation of acid sphingomyelinase in macrophages stimulated with oxidized low-density lipoprotein (LDL) and oxidized LDL immune complexes: role in phagocytosis and cytokine release. Immunology 2012; 136: 30-45.
19. Krishnamurthy K, Wang G, Rokhfeld D, et al., Deoxycholate promotes survival of breast cancer cells by reducing the level of pro-apoptotic ceramide. Breast Cancer Res 2008; 10: R106.
20. Doyle L, Ross DD,. Multidrug resistance mediated by the breast cancer resistance protein BCRP (abcg2). Oncogene 2003; 22: 7340-58.
21. Ni Z, Bikadi Z, Rosenberg MF, et al., Structure and function of the human breast cancer resistance protein (BCRP/abcg2). Curr Drug Metab 2010; 11: 603-17.
22. Natarajan K, Xie Y, Baer MR, et al., Role of breast cancer resistance protein (BCRP/abcg2) in cancer drug resistance. Biochem Pharmacol 2012; 83: 1084-103.
23. Britton KM, Eyre R, Harvey IJ, et al., Breast cancer, side population cells and abcg2 expression. Cancer Lett 2012; 323: 97-105.
24. Teng Y, Liu M, Cowell JK,. Functional interrelationship between the wasf3 and kiss1 metastasis-associated genes in breast cancer cells. Int J Cancer 2011; 129: 2825-35.
25. Krishnamurthy K, Dasgupta S, Bieberich E,. Development and characterization of a novel anti-ceramide antibody. J Lipid Res 2007; 48: 968-75.
26. Silva J, Dasgupta S, Wang G, et al., Lipids isolated from bone induce the migration of human breast cancer cells. J Lipid Res 2006; 47: 724-33.
27. Charafe-Jauffret E, Ginestier C, Iovino F, et al., Aldehyde dehydrogenase 1-positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer. Clin Cancer Res 2010; 16: 45-55.
28. Komuro H, Saihara R, Shinya M, et al., Identification of side population cells (stem-like cell population) in pediatric solid tumor cell lines. J Pediatr Surg 2007; 42: 2040-5.
29. Shen F, Chu S, Bence AK, et al., Quantitation of doxorubicin uptake, efflux, and modulation of multidrug resistance (MDR) in MDR human cancer cells. J Pharmacol Exp Ther 2008; 324: 95-102.
30. Dinkins MB, Dasgupta S, Wang G, et al., Exosome reduction in vivo is associated with lower amyloid plaque load in the 5XFAD mouse model of Alzheimer's disease. Neurobiol Aging 2014; 35: 1792-800.
31. Goler-Baron V, Assaraf YG,. Structure and function of ABCG2-rich extracellular vesicles mediating multidrug resistance. PLoS One 2011; 6: e16007.
32. Jaiswal R, Raymond Grau GE, Bebawy M,. Cellular communication via microparticles: role in transfer of multidrug resistance in cancer. Future Oncol 2014; 10: 655-69.
33. Gouaze-Andersson V, Yu JY, Kreitenberg AJ, et al., Ceramide and glucosylceramide upregulate expression of the multidrug resistance gene mdr1 in cancer cells. Biochim Biophys Acta 2007; 1771: 1407-17.
34. Nakagawa H, Wakabayashi-Nakao K, Tamura A, et al., Disruption of N-linked glycosylation enhances ubiquitin-mediated proteasomal degradation of the human ATP-binding cassette transporter abcg2. FEBS J 2009; 276: 7237-52.
35. Osburn DL, Shao G, Seidel HM, et al., Ligand-dependent degradation of retinoid X receptors does not require transcriptional activity or coactivator interactions. Mol Cell Biol 2001; 21: 4909-18.
36. Yuyama K, Sun H, Mitsutake S, et al., Sphingolipid-modulated exosome secretion promotes the clearance of amyloid-beta by microglia. J Biol Chem 2012; 287: 10977-89.
37. Robert J,. MS-209 schering. Curr Opin Investig Drugs 2004; 5: 1340-7.
38. Meissner K, Heydrich B, Jedlitschky G, et al., The ATP-binding cassette transporter abcg2 (BCRP), a marker for side population stem cells, is expressed in human heart. J Histochem Cytochem 2006; 54: 215-21.
39. Croker AK, Goodale D, Chu J, et al., High aldehyde dehydrogenase and expression of cancer stem cell markers selects for breast cancer cells with enhanced malignant and metastatic ability. J Cell Mol Med 2009; 13: 2236-52.
40. Senkal CE, Ponnusamy S, Rossi MJ, et al., Role of human longevity assurance gene 1 and C18-ceramide in chemotherapy-induced cell death in human head and neck squamous cell carcinomas. Mol Cancer Ther 2007; 6: 712-22.
41. Kawase M, Watanabe M, Kondo T, et al., Increase of ceramide in adriamycin-induced HL-60 cell apoptosis: detection by a novel anti-ceramide antibody. Biochim Biophys Acta 2002; 1584: 104-14.
42. Samanta S, Pursell B, Mercurio AM,. Imp3 protein promotes chemoresistance in breast cancer cells by regulating breast cancer resistance protein (abcg2) expression. J Biol Chem 2013; 288: 12569-73.
43. Nakanishi T, Ross DD,. Breast cancer resistance protein (BCRP/abcg2): its role in multidrug resistance and regulation of its gene expression. Chin J Cancer 2012; 31: 73-99.
44. Perez-Tomas R,. Multidrug resistance: retrospect and prospects in anti-cancer drug treatment. Curr Med Chem 2006; 13: 1859-76.
45. Kahlert C, Kalluri R,. Exosomes in tumor microenvironment influence cancer progression and metastasis. J Mol Med (Berl) 2013; 91: 431-7.
46. Webber J, Yeung V, Clayton A,. Extracellular vesicles as modulators of the cancer microenvironment. Semin Cell Dev Biol 2015. pii: S1084-9521(15)00025-7. doi: 10.1016/j.semcdb.2015.01.013.
47. Wu C, Alman BA,. Side population cells in human cancers. Cancer Lett 2008; 268: 1-9.
48. Zimber A, Gespach C,. Bile acids and derivatives, their nuclear receptors FXR, PXR and ligands: role in health and disease and their therapeutic potential. Anticancer Agents Med Chem 2008; 8: 540-63.
49. Straus DJ, Duvic M, Horwitz SM, et al., Final results of phase II trial of doxorubicin HCl liposome injection followed by bexarotene in advanced cutaneous T-cell lymphoma. Ann Oncol 2014; 25: 206-10.
50. Cramer PE, Cirrito JR, Wesson DW, et al., ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models. Science 2012; 335: 1503-6.
51. Shishodia S, Harikumar KB, Dass S, et al., The guggul for chronic diseases: ancient medicine, modern targets. Anticancer Res 2008; 28: 3647-64.
52. Samudio I, Konopleva M, Safe S, et al., Guggulsterones induce apoptosis and differentiation in acute myeloid leukemia: identification of isomer-specific antileukemic activities of the pregnadienedione structure. Mol Cancer Ther 2005; 4: 1982-92.
53. Xu HB, Xu LZ, Li L, et al., Reversion of P-glycoprotein-mediated multidrug resistance by guggulsterone in multidrug-resistant human cancer cell lines. Eur J Pharmacol 2012; 694: 39-44.
54. Yen WC, Lamph WW,. The selective retinoid X receptor agonist bexarotene (lgd1069, targretin) prevents and overcomes multidrug resistance in advanced breast carcinoma. Mol Cancer Ther 2005; 4: 824-34.